These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19690939)

  • 1. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.
    Rosato E; Borghese F; Pisarri S; Salsano F
    Clin Rheumatol; 2009 Dec; 28(12):1379-84. PubMed ID: 19690939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon.
    Salsano F; Letizia C; Proietti M; Rossi C; Proietti AR; Rosato E; Pisarri S
    Int J Immunopathol Pharmacol; 2005; 18(4):761-70. PubMed ID: 16388726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
    Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
    Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
    Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
    Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
    J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasimogen activator.
    Lakshminarayanan S; Vázquez-Abad D; Maestrello SJ; Waterman JR
    Clin Exp Rheumatol; 1999; 17(2):260. PubMed ID: 10342058
    [No Abstract]   [Full Text] [Related]  

  • 18. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).
    Mecoli CA; Perin J; Van Eyk JE; Zhu J; Fu Q; Allmon AG; Rao Y; Zeger S; Wigley FM; Hummers LK; Shah AA
    Clin Rheumatol; 2020 Apr; 39(4):1199-1205. PubMed ID: 31858338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan.
    Selenko-Gebauer N; Duschek N; Minimair G; Stingl G; Karlhofer F
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii45-8. PubMed ID: 16987835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic literature review to inform the Portuguese recommendations for the management of Raynaud's phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases.
    Costa E; Cunha-Santos F; Dourado E; Oliveira D; Falzon L; Romão V; Duarte AC; Cordeiro A; Santiago T; Sepriano A
    ARP Rheumatol; 2024 Jul; 3(Apr-Jun):128-144. PubMed ID: 38306796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.